LEMS Treatments Don’t Affect Calcium Channels, Study Finds

LEMS Treatments Don’t Affect Calcium Channels, Study Finds

284494

LEMS Treatments Don’t Affect Calcium Channels, Study Finds

The molecule 3,4-diaminopyridine (3,4-DAP) — approved as Firdapse and Ruzurgi to treat people with Lambert-Eaton myasthenic syndrome (LEMS) — works to directly induce the release of chemical messengers by binding to potassium channels, without affecting calcium channels as previously thought, a study reported.  The study, “A high affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs,” was published in the Journal of Biological Chemistry.  LEMS is characterized by the…

You must be logged in to read/download the full post.